QLYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy QLYS now. The setup is improving (MACD turning up, price sitting right on the 132 pivot), options positioning is strongly bullish (very low put/call), and fundamentals support the move (Q3 2025 showed accelerating growth and strong margins). With an impatient profile, the risk/reward is attractive here because immediate upside levels are nearby (135–137 resistance zone) while the technical invalidation is clear (loss of 129 support).
Intellectia Proprietary Trading Signals
Price/Trend: QLYS is trading at 132.09, essentially on the key pivot (132.078), indicating a decision point rather than an extended move. Momentum: MACD histogram is positive (0.306) and expanding, which typically supports a developing upswing. RSI: RSI(6) at 45.6 is neutral—no overbought pressure, but also not a strong oversold bounce signal. Moving averages: Converging MAs suggest consolidation that can break either way; MACD tilt favors upside. Levels: Support S1=129.08 (then S2=127.23). Resistance R1=135.07 (then R2=136.92). Given today’s location at pivot, a push toward 135–137 is the near-term technical objective. Pattern/Stats: Similar-pattern model shows a 60% probability of modest gains (+0.79% next day, +0.69% next week, +0.91% next month), consistent with a slow grind higher rather than a big breakout.
Fundamentals momentum: Q3 2025 delivered a third consecutive quarter of revenue growth acceleration (per sell-side commentary) and meaningful margin upside.
Hedge fund flow: “Hedge Funds are Buying” with a large reported increase in buying over the last quarter.
Event catalyst ahead: Next earnings (QDEC
on 2026-02-05 after hours can act as a near-term catalyst window.
Options sentiment: Put/call ratios are strongly bullish, aligning with a near-term upside bias.
Mixed near-term outlook: Some analysts flagged a more mixed Q4 outlook and concerns around new logo growth and low-single-digit NRR.
Street disagreement: Multiple Underweight/Hold/Neutral ratings remain, with some price targets below the current price (e.g., 117), which can cap enthusiasm.
No supportive news flow this week: Lack of fresh positive headlines means the stock may rely on technicals/positioning and the next earnings catalyst.
Latest quarter: 2025/Q3. Growth: Revenue 169.882M (+10.41% YoY), showing healthy top-line expansion. Profitability: Net income 50.346M (+8.95% YoY) and EPS 1.39 (+12.10% YoY) indicate earnings growing faster than revenue. Margins: Gross margin 83.64% (+2.93% YoY) confirms strong and improving unit economics—supportive for valuation and durability.
Recent trend: After Q3 2025 results, multiple firms raised price targets (UBS to 150, Canaccord to 160, Northland to 162; Piper upgraded to Neutral with PT 135), reflecting improved confidence in execution and margins. However, bears still exist (JPMorgan and Morgan Stanley stayed Underweight with PT 117; Morgan Stanley raised PT but kept Underweight). Wall Street pros: Accelerating growth, record/strong margins, improving execution around ETM/ROC and platform modernization. Wall Street cons: Continued concerns about new logo growth and NRR staying low-single-digit; some firms want more proof of newer product ramps/conversions before turning more bullish. Net take: Mixed-to-improving sell-side stance with upside skew versus the current price (132) given several 150–165 targets, but not a unanimous bullish consensus.
